NantKwest (NK) said Tuesday fresh data in a trial of patients who have received off-the-shelf aNK and/or haNK natural killer cell therapy in combination with immunotherapeutic agents in advanced solid tumors show “durable complete responses in 5 out of 35 patients with highly refractory late-stage cancers across multiple tumor types.”

Shares jumped more than 5% during pre-market trade.

All the five patients remain alive to date, ranging from four to 24 months from the onset of response, the company said.

“These early signals of efficacy have now provided us a pathway to the development of registration trials across triple negative breast cell and Merkel cell carcinoma,” said NantKwest Chief Executive Patrick Soon-Shiong in a statement.

Separately, the company said the Food and Drug Administration has authorized a trial utilizing CD19 T-haNK to treat refractory diffuse large B-cell lymphoma as well as its investigational new drug filing of PD-L1 T-haNK for refractory solid tumors.